The results showed that cell viability was significantly inhibited after sorafenib treatment, and the liver cancer cell viability was lower in ORMDL3-silenced group, which is consistent with the higher cell inhibition rate in ORMDL3-silenced group (Fig. 1C). Here, ORMDL3 is linked to liver cancer.